AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer

뉴스 본문을 불러오고 있어요.

AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer | 웨이프 WAPE

AstraZeneca Announced At ESMO Sunday, TAGRISSO Plus Savolitinib Extended Median Overall Survival By Nearly Five Months In Patients With EGFRm Lung Cancer

기사 요약

관련 종목

댓글 —